Previous close | 0.2600 |
Open | 0.2550 |
Bid | 0.2550 x 438200 |
Ask | 0.2600 x 19047400 |
Day's range | 0.2550 - 0.2600 |
52-week range | 0.1400 - 0.2800 |
Volume | |
Avg. volume | 112,054 |
Market cap | 91.092M |
Beta (5Y monthly) | 1.13 |
PE ratio (TTM) | ∞ |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced participation in the following psychedelics research and industry conferences:
Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal quarter results for the three and six months ended February 28, 2022 ("Q2 2022").